Artelo Biosciences, Inc.
Every calculator, already run for ARTL
Open the full toolkit →You have the numbers on ARTL. Get the argument.
A written report on which of these readings actually decide the outcome for Artelo Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Ownership & short interest
About Artelo Biosciences, Inc.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral…
ARTL — frequently asked
Is ARTL a buy right now?
Wall Street's consensus rating on Artelo Biosciences, Inc. is none. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Artelo Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Artelo Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ARTL research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Artelo Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.